On March 17, 2026 Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, reported three poster presentations, including one late-breaking presentation, at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting being held in San Diego, CA from April 17-22, 2026.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"These data further demonstrate our differentiated approach leveraging our AP3 platform to identify therapeutic candidates and combinations with the greatest potential for clinical impact," said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and co-founder of Acrivon. "Our data show that a key resistance mechanism to Topo1 inhibitors, the most common ADC payload, is the activation of the CHK1/2 DNA damage repair response, which can be overcome by ACR-368 treatment resulting in synergistic tumor cell killing. We also found that ACR-2316 induced mitochondrial and nuclear genomic damage resulting in activation of the innate and adaptive immune system, leading to complete tumor regression and lasting immune protection in mice when combined with immune checkpoint inhibition."
Poster Details:
Title Potent synergy between CHK1/2 inhibitor ACR-368 and the ADC payload topoisomerase 1 inhibitor: Rationale for ADC + ACR-368 combination therapy
Date and Time Sunday, April 19, 2026; 2:00 p.m. – 5:00 p.m. PT
Session Experimental and Molecular Therapeutics: DNA Damage and Repair 1
Poster Number 239
Title ACR-368 synergizes with PD-L1 blockade by coordinated activation of adaptive and innate immunity pathways to achieve robust anti-tumor efficacy
Date and Time Monday, April 20, 2026; 9:00 a.m. – 12:00 p.m. PT
Session Late-Breaking Research: Immunology 2
Poster Number LB152
Title Treatment with ACR-2316, a potential first- and best-in-class WEE1/PKMYT1 inhibitor, combined with anti-PD-L1 induces complete tumor regression with durable immune memory
Date and Time Monday, April 20, 2026; 2:00 p.m. – 5:00 p.m. PT
Session Clinical Research: Combination Immunotherapies
Poster Number 3789
(Press release, Acrivon Therapeutics, MAR 17, 2026, View Source [SID1234663658])